Sign in
CompletedNo phase

Myopia Control With a Innovative Spectacle Lens

Key facts

Who runs it
Essilor International
Where
Boston, Chicago, Houston, Longwood, New York, Pittsburg, Pittsburgh, San Diego, and Vestal, United StatesSee the 9 sites
Trial code
Status
Completed
People taking part
159 people enrolled
Started
29 Dec 2021
Ended
20 Oct 2025
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • innovative myopia control spectacle lens
  • Single vision spectacle lens
Record updated
22 December 2025

Who can take part

Age
6 years to 12 years
Sex
Women and men
Healthy volunteers
Can take part
Show the full registry criteria (14)Hide the full registry criteria

Who can take part

  • Equal to or greater than 6 years and not older than 12 years at time of informed consent and assent
  • Spherical equivalent refractive error (SER) by manifest refraction between -0.75 and -4.50 D in each eye
  • Astigmatism, if present, of not more than 1.50 D
  • Difference in SER between the two eyes (Anisometropia) by manifest refraction not more than 1.00 D
  • Best corrected visual acuity in each eye equal to or better than +0.10 logMAR (≥ 20/25 as Snellen)
  • Agree to wear spectacles for ≥10 hours/day at least 6 days/week
  • Willingness and ability to participate in trial for 3 years and attend scheduled visits

Who cannot take part

  • Current use of ocular or systemic medications which, in the investigator's opinion, may significantly affect pupil size, accommodation or refractive state
  • History of myopia control intervention (e.g., atropine, orthokeratology, multifocal contact lenses, etc.)
  • Any ocular or systemic condition known to affect refractive status (e.g., keratoconus, diabetes, Down's syndrome, etc.)
  • Strabismus by cover test at near or distance wearing correction
  • Amblyopia
  • Current or anticipated use of growth hormones
  • Participation in any clinical study within 30 days of the Baseline visit

Where in United States

  • New England College of OptometryBoston, United States
  • Illinois College of OptometryChicago, United States
  • Mann Eye InstituteHouston, United States
  • Sabal Eye CareLongwood, United States
  • SUNY College of OptometryNew York, United States
  • Kannarr Eye CarePittsburg, United States
  • UPMC Children's Hospital of PittsburghPittsburgh, United States
  • Scripps Poway OptometrySan Diego, United States
  • Sacco Eye GroupVestal, United States

About the trial

What the trial wants to find out

The purpose of this study is to demonstrate that the test spectacle lens is safe and effective in slowing myopia progression in children.

The 2 groups in the trial

  • Innovative myopia control spectacle lensTreatment being tested
  • Single vision spectacle lensPlacebo, for comparison

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Clinical Evaluation of A Innovative Spectacle Lens in Slowing Myopia Progression
Publications
Record updated
22 December 2025